Case report highlights the occurrence of paralytic ileus in a multiple myeloma patient on bortezomib, suggesting careful monitoring.
Bortezomib is a targeted anti - cancer medication used primarily to treat Multiple Myeloma and Mantle Cell Lymphoma in adults. It is classified as a Protease Inhibitor, which works by reversibly inhibiting the protein complex responsible for degrading damaged proteins within cells.[1] We report the case of a patient with Multiple Myeloma who developed Paralytic Ileus while on Bortezomib.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: